Display options
Cite
Alavi M, Omidvari S, Mehdizadeh A, et al. Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid. World J Nucl Med. 2015;14(2):109-15doi: 10.4103/1450-1147.157124.
Alavi, M., Omidvari, S., Mehdizadeh, A., Jalilian, A. R., & Bahrami-Samani, A. (2015). Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid. World journal of nuclear medicine, 14(2), 109-15. https://doi.org/10.4103/1450-1147.157124
Alavi, Mehrosadat, et al. "Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid." World journal of nuclear medicine vol. 14,2 (2015): 109-15. doi: https://doi.org/10.4103/1450-1147.157124
Alavi M, Omidvari S, Mehdizadeh A, Jalilian AR, Bahrami-Samani A. Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid. World J Nucl Med. 2015 May-Aug;14(2):109-15. doi: 10.4103/1450-1147.157124. PMID: 26097421; PMCID: PMC4455166.
Copy Download .nbib Format: NLM
Share it on

World J Nucl Med. 2015 May-Aug;14(2):109-15. doi: 10.4103/1450-1147.157124.

Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid.

World journal of nuclear medicine

Mehrosadat Alavi, Shapour Omidvari, Alireza Mehdizadeh, Amir R Jalilian, Ali Bahrami-Samani

Affiliations

  1. Department of Nuclear Medicine, Shiraz University of Medical Sciences, Shiraz, Tehran, Iran.
  2. Department of Radiotherapy, Shiraz University of Medical Sciences, Shiraz, Tehran, Iran.
  3. Department of Medical Physics and Engineering, Shiraz University of Medical Sciences, Shiraz, Tehran, Iran.
  4. Department of Radiopharmaceutical Research and Development Laboratory, Nuclear Science and Technology Research Institute, Tehran, Iran.

PMID: 26097421 PMCID: PMC4455166 DOI: 10.4103/1450-1147.157124

Abstract

(177)Lu-ethylenediaminetetramethylene phosphonic acid (EDTMP) is presently suggested as an excellent bone seeking radionuclide for developing metastatic bone pain (MBP) palliation agent owing to its suitable nuclear decay characteristics. To find the exact dosage and its efficiency, this clinical study was performed on the human being, using (177)Lu-EDTMP for MBP palliation. (177)Lu-EDTMP was prepared by Iran, atomic energy organization. Thirty consecutive patients with determined tumors, incontrollable MBP, and positive bone scan at 4 weeks before the beginning of the study participated in this study in the nuclear medicine ward. (177)Lu-EDTMP in the form of sterile slow IV injection was administered with a dose of 29.6 MBq/kg. Short form of brief pain inventory questionnaire was used to evaluate the efficiency of the intervention. Questionnaires were filled out by an expert nuclear physician every 2 weeks while the cell blood count was also checked every 2 weeks up to 12 weeks for evaluation of bone marrow suppression and hematological toxicity. Furthermore, whole body scan was done at days 1, 3, and 7. Twenty-five patients showed a significant pain relief since 2 weeks after the injection, and continued until the end of the follow up period (12 weeks). There were no significant early complications such as bone marrow suppression, hematological toxicity, and no systemic adverse effects. No complication was observed in renal function. Twenty one patients showed flare phenomenon that was started after the 12.2 ± 1.78 h lasting for 38.4 ± 23.08. Sixteen patients (53%) were completely treated; nine patients (30%) showed a partial response, and five patients (17%) had no response to treatment. Total response to treatment was achieved in 25 patients (83%). At the end of the evaluation, no bone marrow suppression or hematologic toxicity was observed. (177)Lu-EDTMP has shown suitable physical and biological properties with good results in long term bone pain relief for patients with bone metastasis.

Keywords: 177Lu-ethylenediaminetetramethylene phosphonic acid; bone pain palliation; metastasis; nuclear medicine; targeted radionuclide therapy

References

  1. Semin Radiat Oncol. 2000 Apr;10(2):103-14 - PubMed
  2. J Nucl Med. 2001 Jun;42(6):895-906 - PubMed
  3. Breast Cancer Res Treat. 2001 Mar;66(2):101-9 - PubMed
  4. Chem Rev. 1999 Sep 8;99(9):2269-92 - PubMed
  5. Cancer Treat Rev. 2003 Aug;29(4):321-7 - PubMed
  6. Semin Nucl Med. 1992 Jan;22(1):11-6 - PubMed
  7. Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S171-8 - PubMed
  8. J Nucl Med. 2004 Aug;45(8):1358-65 - PubMed
  9. J Nucl Med. 2005 Jan;46 Suppl 1:38S-47S - PubMed
  10. Nucl Med Biol. 2005 Apr;32(3):269-78 - PubMed
  11. J Clin Oncol. 2005 Apr 20;23(12):2754-62 - PubMed
  12. Nucl Med Commun. 2006 Aug;27(8):661-8 - PubMed
  13. Clin Nucl Med. 2006 Oct;31(10):605-10 - PubMed
  14. Nucl Med Commun. 2007 Apr;28(4):245-50 - PubMed
  15. Appl Radiat Isot. 2008 Sep;66(9):1196-205 - PubMed
  16. J Clin Oncol. 2008 May 1;26(13):2124-30 - PubMed
  17. Cancer Biother Radiopharm. 2008 Apr;23(2):202-13 - PubMed
  18. Nucl Med Biol. 2008 Jul;35(5):589-97 - PubMed
  19. J Endocrinol Invest. 2009 Apr;32(4):360-9 - PubMed
  20. J Pain Symptom Manage. 2010 Feb;39(2):230-40 - PubMed
  21. Nucl Med Biol. 2010 Feb;37(2):215-26 - PubMed
  22. Appl Radiat Isot. 2011 Sep;69(9):1267-73 - PubMed
  23. Acta Oncol. 2012 Jan;51(1):86-96 - PubMed
  24. Nucl Med Commun. 2012 Jan;33(1):90-6 - PubMed
  25. Iran J Pharm Res. 2012 Winter;11(1):137-44 - PubMed
  26. Asia Ocean J Nucl Med Biol. 2013 Spring;1(1):27-31 - PubMed
  27. J Nucl Med. 1987 Apr;28(4):495-504 - PubMed
  28. Pain. 1982 Nov;14(3):303-10 - PubMed
  29. J Nucl Med. 1993 Jul;34(7):1031-6 - PubMed
  30. Ann Acad Med Singapore. 1994 Mar;23(2):129-38 - PubMed
  31. J Nucl Med. 1993 Nov;34(11):1839-44 - PubMed
  32. Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):805-13 - PubMed
  33. Phys Med Biol. 1996 Oct;41(10):2027-42 - PubMed
  34. J Clin Oncol. 1998 Apr;16(4):1574-81 - PubMed
  35. Cancer Prev Control. 1998 Apr;2(2):79-87 - PubMed

Publication Types